Cargando…
United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis
BACKGROUND: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. METHODS:...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259275/ https://www.ncbi.nlm.nih.gov/pubmed/33939892 http://dx.doi.org/10.1002/ueg2.12060 |
_version_ | 1783718642256445440 |
---|---|
author | Schol, Jolien Wauters, Lucas Dickman, Ram Drug, Vasile Mulak, Agata Serra, Jordi Enck, Paul Tack, Jan |
author_facet | Schol, Jolien Wauters, Lucas Dickman, Ram Drug, Vasile Mulak, Agata Serra, Jordi Enck, Paul Tack, Jan |
author_sort | Schol, Jolien |
collection | PubMed |
description | BACKGROUND: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. METHODS: A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements. RESULTS: The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine‐2 antagonists and 5‐HT(4) receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long‐term prognosis of gastroparesis depends on the cause. CONCLUSIONS AND INFERENCES: A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis. |
format | Online Article Text |
id | pubmed-8259275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82592752021-07-12 United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis Schol, Jolien Wauters, Lucas Dickman, Ram Drug, Vasile Mulak, Agata Serra, Jordi Enck, Paul Tack, Jan United European Gastroenterol J Neurogastroenterology BACKGROUND: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. METHODS: A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements. RESULTS: The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine‐2 antagonists and 5‐HT(4) receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long‐term prognosis of gastroparesis depends on the cause. CONCLUSIONS AND INFERENCES: A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis. John Wiley and Sons Inc. 2021-05-03 /pmc/articles/PMC8259275/ /pubmed/33939892 http://dx.doi.org/10.1002/ueg2.12060 Text en © 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Neurogastroenterology Schol, Jolien Wauters, Lucas Dickman, Ram Drug, Vasile Mulak, Agata Serra, Jordi Enck, Paul Tack, Jan United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis |
title | United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis |
title_full | United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis |
title_fullStr | United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis |
title_full_unstemmed | United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis |
title_short | United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis |
title_sort | united european gastroenterology (ueg) and european society for neurogastroenterology and motility (esnm) consensus on gastroparesis |
topic | Neurogastroenterology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259275/ https://www.ncbi.nlm.nih.gov/pubmed/33939892 http://dx.doi.org/10.1002/ueg2.12060 |
work_keys_str_mv | AT scholjolien unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis AT wauterslucas unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis AT dickmanram unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis AT drugvasile unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis AT mulakagata unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis AT serrajordi unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis AT enckpaul unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis AT tackjan unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis AT unitedeuropeangastroenterologyuegandeuropeansocietyforneurogastroenterologyandmotilityesnmconsensusongastroparesis |